Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · IEX Real-Time Price · USD
3.83
-0.14 (-3.53%)
At close: Dec 29, 2023, 4:00 PM
3.90
+0.07 (1.83%)
After-hours: Dec 29, 2023, 7:13 PM EST
Company Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.
The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.
It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.
The company was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | David P. Luci CPA, Esq., J.D. |
Contact Details
Address: 259 Liberty Avenue Staten Island, New York 10305 United States | |
| Phone | 917-533-1469 |
| Website | acurxpharma.com |
Stock Details
| Ticker Symbol | ACXP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001736243 |
| CUSIP Number | 00510M104 |
| ISIN Number | US00510M1045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert J. DeLuccia | Co-Founder and Executive Chairman |
| David P. Luci CPA, CPA, Esq., J.D. | Corporate Secretary, Co-Founder, President, Chief Executive Officer and Director |
| Robert G. Shawah CPA, CPA | Co-Founder and Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2023 | 8-K | Current Report |
| Nov 15, 2023 | 424B5 | Filing |
| Nov 14, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 3, 2023 | 8-K | Current Report |
| Oct 2, 2023 | 8-K | Current Report |
| Aug 14, 2023 | 8-K | Current Report |
| Aug 11, 2023 | 10-Q | Quarterly Report |
| Jul 13, 2023 | 424B3 | Prospectus |
| Jul 10, 2023 | EFFECT | Notice of Effectiveness |